Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/283034
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Valent, Peter | - |
dc.contributor.author | Hartmann, Karin | - |
dc.contributor.author | Schwaab, Juliana | - |
dc.contributor.author | Álvarez-Twose, Iván | - |
dc.contributor.author | Brockow, Knut | - |
dc.contributor.author | Bonadonna, Patrizia | - |
dc.contributor.author | Hermine, Olivier | - |
dc.contributor.author | Niedoszytko, Marek | - |
dc.contributor.author | Carter, Melody C. | - |
dc.contributor.author | Hoermann, Gregor | - |
dc.contributor.author | Sperr, Wolfgang R. | - |
dc.contributor.author | Butterfield, Joseph H. | - |
dc.contributor.author | Ustun, Celalettin | - |
dc.contributor.author | Zanotti, Roberta | - |
dc.contributor.author | Radia, Deepti | - |
dc.contributor.author | Castells, Mariana | - |
dc.contributor.author | Triggiani, Massimo | - |
dc.contributor.author | Schwartz, Lawrence B. | - |
dc.contributor.author | Orfao, Alberto | - |
dc.contributor.author | George, Tracy I. | - |
dc.date.accessioned | 2022-11-16T14:00:05Z | - |
dc.date.available | 2022-11-16T14:00:05Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier | doi: 10.1016/j.jaip.2022.03.007 | - |
dc.identifier | e-issn: 2213-2198 | - |
dc.identifier.citation | Journal of Allergy and Clinical Immunology: In Practice 10(8): 1999-2012.e6 (2022) | - |
dc.identifier.uri | http://hdl.handle.net/10261/283034 | - |
dc.description.abstract | Mastocytosis is a myeloid neoplasm defined by expansion and focal accumulation of clonal mast cells (MCs) in one or more organs. The disease exhibits a complex pathology and may be complicated by MC activation, bone abnormalities, neurological problems, gastrointestinal symptoms, and/or hematologic progression. The World Health Organization divides mastocytosis into cutaneous forms, systemic mastocytosis (SM) and MC sarcoma. In most patients with SM, somatic mutations in KIT are detected. Patients with indolent SM have a normal to near-normal life expectancy, whereas patients with advanced SM, including aggressive SM and MC leukemia, have a poor prognosis. In those with advanced SM, multiple somatic mutations and an associated hematologic neoplasm may be detected. Mediator-related symptoms can occur in any type of mastocytosis. Symptoms may be mild, severe, or even life-threatening. In patients with severe acute symptoms, an MC activation syndrome may be diagnosed. In these patients, relevant comorbidities include IgE-dependent and IgE-independent allergies. Management of patients with SM is an emerging challenge in daily practice and requires in-depth knowledge and a multidisciplinary and personalized approach with selection of appropriate procedures and interventions. In this article, we review the current knowledge on SM and MC activation syndrome, with emphasis on multidisciplinary aspects in diagnosis and patient-specific management. In addition, we provide a user’s guide for application of markers, algorithms, prognostic scores, and treatments for use in daily practice. | - |
dc.description.sponsorship | This work was supported in part by the Austrian Science Fund (FWF; projects F4704 and P32470-B to P.V.) and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (to M.C.C. and D.D.M.). The content is solely the responsibility of the authors and does not represent the official views of the NIH. | - |
dc.format | application/pdf | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isversionof | Publisher's version | - |
dc.rights | openAccess | - |
dc.subject | Mast cells | - |
dc.subject | KIT | - |
dc.subject | Tryptase | - |
dc.subject | IgE | - |
dc.subject | Allergy | - |
dc.subject | MCAS | - |
dc.subject | Personalized medicine | - |
dc.title | Personalized management strategies in mast cell disorders: ECNM-AIM User's guide for daily clinical practice | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1016/j.jaip.2022.03.007 | - |
dc.relation.publisherversion | http://dx.doi.org/10.1016/j.jaip.2022.03.007 | - |
dc.date.updated | 2022-11-16T14:00:05Z | - |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/ | - |
dc.contributor.funder | Austrian Science Fund | - |
dc.contributor.funder | Fundación de la Sociedad Española de Alergia e Inmunología Clínica | - |
dc.contributor.funder | National Institutes of Health (US) | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100002428 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100009090 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/100000002 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Personalized Management Strategies_Valent_PV_Art2022.pdf | 768,33 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
31
checked on 18-may-2024
WEB OF SCIENCETM
Citations
22
checked on 25-feb-2024
Page view(s)
75
checked on 22-may-2024
Download(s)
238
checked on 22-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons